Additionally, a different HER2 expression between primary cancer and corresponding metastases has also been reported (mean rate 7%), probably related to a clonal selection throughout tumor progression or, alternatively, to intra-tumor HER2 heterogeneity [91,92,93,94,95,96,97,98,99]. This evidence concerns the gene ERBB2 and cancer.